Skip Content
You are currently on the new version of our website. Access the old version .
Brain SciencesBrain Sciences
  • Erratum
  • Open Access

22 May 2020

Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176

,
,
,
,
,
,
and
1
Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
2
Department of Medicine, Autonomous University of Barcelona, 08193 Barcelona, Spain
3
Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
4
Movement Disorders Unit, Neurology Department, Hospital Universitario San Roque, 35001 Las Palmas, Spain
This article belongs to the Special Issue Frontiers in Parkinson’s Disease (PD)
We would like to submit the following erratum to our recently published paper [1] due to the errors in the abstract. We request (1) the removal of the word “motor” from the first line of the abstract, so that the sentence reads: “Safinamide is an approved drug for the treatment of fluctuations in Parkinson’s disease (PD)”, and (2) that the word “OFF” is changed to “ON” in line 6 of the abstract, so that the sentence reads: “Safinamide significantly improves the mean daily ON time without troublesome dyskinesias.”
We apologize for any inconvenience caused to our readers.

Conflicts of Interest

The authors declare no conflict of interest.

Reference

  1. Pagonabarraga, J.; Arbelo, J.M.; Grandas, F.; Luquin, M.-R.; Martínez Martín, P.; Rodríguez-Oroz, M.C.; Valldeoriola, F.; Kulisevsky, J. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176. [Google Scholar] [CrossRef] [PubMed]

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.